TAMPA, Fla., April 25, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (formerly known as Better Choice Company Inc.) (NYSE American: BTTR) (the “Company”), a leading global health and wellness company, today announced that it will distribute (the “Spin-Out Distribution”) to its stockholders of record as of Tuesday, April 23, 2025 (the “Record Stockholders”) one share of Class A Common Stock, par value $0.001, of Halo Spin-Out SPV Inc., a Delaware corporation (“Halo SPV”), for every one share of common ...

文章核心观点 AEON Biopharma收到纽交所美国公司接受其恢复合规计划的通知 并获至2026年8月3日的期限来重新符合持续上市标准 [1][2] 分组1：计划相关 - 纽交所美国公司接受公司此前提交的恢复符合持续上市标准的计划 [1] - 公司获至2026年8月3日的期限来重新符合持续上市标准 期间将接受纽交所美国公司的定期审查 [2] - 若公司到2026年8月3日未重新符合上市标准 或在计划期间未取得与计划相符的足够进展 纽交所美国公司可能启动摘牌程序 [2] 分组2：公司概况 - 公司是临床阶段生物制药公司 专注开发肉毒杆菌毒素复合物ABP - 450用于治疗衰弱性疾病 初步聚焦神经科学市场 [3] - ABP - 450与Evolus旗下用于美容的Jeuveau为同一肉毒杆菌毒素复合物 由Daewoong按cGMP标准生产 生产设施获美、加、欧监管机构批准 [3] - 该产品在墨西哥和印度获生物类似药批准 公司拥有其在美国、加拿大、欧盟、英国等地区的治疗用途独家开发和分销权 [3] 分组3：联系方式 - 投资者联系人为Corey Davis博士 来自LifeSci Advisors 电话+1 212 915 2577 邮箱cdavis@lifesciadvisors.com [8]

Lenexa, KS, April 25, 2025 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (Nasdaq: DGLY) (the “Company”) today announced it received a delinquency notification letter from Nasdaq on April 23, 2025, which indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the delayed filing of the Company’s Annual Report on Form 10-K for the period ended December 31, 2024 (the “Annual Report”). The Nasdaq Listing Rule requires listed companies to timely file all required periodic fina ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of April 15, 2025, short interest in 3,143 Nasdaq Global MarketSM securities totaled 13,211,633,004 shares compared with 13,072,444,217 shares in 3,140 Global Market issues reported for the prior settlement date of March 31, 2025. The mid-April short interest represents 1.76 days compared with 2.64 days for the prior reporting period. Short interest in 1,634 securities on The Nasdaq Capital MarketSM totaled 2,609,354,721 shares a ...

HOUSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that it will issue its first quarter 2025 earnings release on Wednesday, May 14, 2025 after the market close and host a conference call to discuss its financial and operating results on Thursday, May 15, 2025 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time). Interested parties in the United States and Canada may participate toll-free by dialing (833) 816-1385. International parties ...

Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude’s efforts to discover and develop selective KAT6A degraders, including preclinical data, demonstrating potential for a differentiated efficacy and safety profile WILMINGTON, Del., April 25, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announc ...

Podium presentation showcases the clinical application of Precise™ MRDSALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared at the American Association for Cancer Research (AACR) Annual Meeting that highlights the performance of the Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). A podium presentation titled “Phase 2 trial o ...

TORONTO, April 25, 2025 (GLOBE NEWSWIRE) -- Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to announce it has received conditional acceptance from the TSX Venture Exchange (the "TSXV") to commence an early warrant exercise incentive program (the “Program”) intended to encourage the early exercise of up to 15,000,000 outstanding common share purchase warrants (the “Eligible Warrants”) originally issued in connection with the Company’s private placement financing that closed on Nov ...

ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01. The issuance comprises 589,974 registered shares, reflecting the settlement of 310,941 shares issued in connection with the exercise of equity awards under the Company’s Stock Option and Incentive Plan Regulation and 279,033 shares issued through EBAC warran ...

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano Med Additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to ...